

# Hideo Wada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1926984/publications.pdf>

Version: 2024-02-01

240  
papers

9,487  
citations

53789

45  
h-index

46795

89  
g-index

249  
all docs

249  
docs citations

249  
times ranked

6297  
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1327-1330.	3.4	1,875
2	Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1327-30.	3.4	709
3	Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 761-767.	3.8	366
4	Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. <i>Journal of Intensive Care</i> , 2014, 2, 15.	2.9	239
5	Expert consensus for the treatment of disseminated intravascular coagulation in Japan. <i>Thrombosis Research</i> , 2010, 125, 6-11.	1.7	222
6	Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 975-979.	3.4	208
7	Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt DIC. <i>American Journal of Hematology</i> , 2003, 74, 17-22.	4.1	166
8	Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun. <i>Thrombosis and Haemostasis</i> , 1995, 74, 848-852.	3.4	138
9	Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. <i>Thrombosis Journal</i> , 2016, 14, 42.	2.1	130
10	Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWFâ€œcleaving proteaseâ€œf activity. <i>Transfusion</i> , 2002, 42, 572-580.	1.6	121
11	Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. <i>American Journal of Hematology</i> , 1992, 39, 20-24.	4.1	107
12	The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. <i>Seminars in Hematology</i> , 2004, 41, 68-74.	3.4	104
13	Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7036-7041.	7.1	100
14	Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2011, 105, 40-44.	3.4	98
15	Elevated levels of soluble fibrin or Dâ€œdimer indicate high risk of thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1253-1258.	3.8	95
16	Disseminated intravascular coagulation. <i>Clinica Chimica Acta</i> , 2004, 344, 13-21.	1.1	93
17	Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. <i>American Journal of Hematology</i> , 1993, 44, 112-116.	4.1	90
18	Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation. <i>Thrombosis Research</i> , 2001, 104, 1-6.	1.7	88

#	ARTICLE	IF	CITATIONS
19	Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. <i>American Journal of Hematology</i> , 2004, 76, 225-229.	4.1	81
20	Evaluation of New Japanese Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically Ill Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 71-76.	1.7	77
21	Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal <i>Escherichia coli</i> sepsis and in the human model of endotoxemia: Toward a better definition of DIC. <i>Critical Care Medicine</i> , 2000, 28, S12-S19.	0.9	75
22	High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. <i>American Journal of Hematology</i> , 2003, 72, 1-7.	4.1	75
23	Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. <i>International Journal of Hematology</i> , 2017, 106, 3-15.	1.6	75
24	Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. <i>Thrombosis Journal</i> , 2018, 16, 14.	2.1	75
25	Hemostatic Abnormalities and Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 772-778.	2.7	73
26	Hemostatic study before onset of disseminated intravascular coagulation. <i>American Journal of Hematology</i> , 1993, 43, 190-194.	4.1	72
27	Disseminated intravascular coagulation: Testing and diagnosis. <i>Clinica Chimica Acta</i> , 2014, 436, 130-134.	1.1	69
28	Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1993, 44, 101-105.	4.1	68
29	Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. , 1996, 51, 255-260.		68
30	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. <i>Thrombosis Research</i> , 2012, 130, e129-e133.	1.7	63
31	Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2013, 54, 238-246.	2.2	62
32	Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. <i>Thrombosis and Haemostasis</i> , 1995, 74, 848-52.	3.4	61
33	Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and Related Diseases. <i>Thrombosis Research</i> , 2012, 129, 598-602.	1.7	60
34	Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. , 1998, 58, 189-194.		58
35	Elevated Levels of Prothrombin Fragment 1 + 2 Indicate High Risk of Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 279-285.	1.7	58
36	Diagnostic Criteria and Laboratory Tests for Disseminated Intravascular Coagulation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 67-76.	0.8	56

#	ARTICLE	IF	CITATIONS
37	Hemostatic molecular markers before the onset of disseminated intravascular coagulation. American Journal of Hematology, 1999, 60, 273-278.	4.1	55
38	Blood-Brain Barrier Permeability of the Demented Elderly as Studied by Cerebrospinal Fluid-Serum Albumin Ratio.. Internal Medicine, 1998, 37, 509-513.	0.7	54
39	Coagulent and fibrinolytic activities in the leukemic cell lysates. Thrombosis Research, 1983, 30, 315-322.	1.7	51
40	Negative predictive value of d-dimer for diagnosis of venous thromboembolism. International Journal of Hematology, 2008, 87, 250-255.	1.6	51
41	Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Critical Care, 2016, 20, 287.	5.8	51
42	Plasma level of tumor necrosis factor in disseminated intravascular coagulation. American Journal of Hematology, 1991, 37, 147-151.	4.1	50
43	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Critical Care, 2014, 18, 497.	5.8	50
44	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 415-419.	3.8	50
45	The effects of lactate and $\beta$ -hydroxybutyrate on the energy metabolism and neural activity of hippocampal slices from adult and immature rat. Developmental Brain Research, 1997, 101, 1-7.	1.7	49
46	Frequency of Abnormal Biphasic aPTT Clot Waveforms in Patients with Underlying Disorders Associated with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 185-192.	1.7	48
47	Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thrombosis Research, 2011, 128, 186-190.	1.7	48
48	A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt DIC diagnostic criteria: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1442-1444.	3.8	48
49	Diagnosis of deep vein thrombosis by plasma-soluble fibrin or D-dimer. American Journal of Hematology, 2005, 79, 274-280.	4.1	47
50	Are Fibrin-Related Markers Useful for the Diagnosis of Thrombosis?. Seminars in Thrombosis and Hemostasis, 2008, 34, 033-038.	2.7	45
51	Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Critical Care Medicine, 2001, 29, 326-334.	0.9	44
52	Cut-off values of D-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery. International Journal of Hematology, 2009, 89, 572-576.	1.6	43
53	Plasma Level of IL-1 $\beta$ in Disseminated Intravascular Coagulation. Thrombosis and Haemostasis, 1991, 65, 364-368.	3.4	43
54	Tissue factor expression in endothelial cells in health and disease. Blood Coagulation and Fibrinolysis, 1995, 6, S26-S31.	1.0	42

#	ARTICLE	IF	CITATIONS
55	Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. <i>Journal of Intensive Care</i> , 2019, 7, 32.	2.9	42
56	Hemostatic abnormalities in the acute phase of trauma. <i>Thrombosis Research</i> , 2010, 126, 1-2.	1.7	41
57	Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. <i>International Journal of Hematology</i> , 2014, 100, 437-442.	1.6	41
58	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. <i>Thrombosis Research</i> , 2019, 179, 11-14.	1.7	41
59	A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 439-445.	1.7	40
60	The effects of glucose, mannose, fructose and lactate on the preservation of neural activity in the hippocampal slices from the guinea pig. <i>Brain Research</i> , 1998, 788, 144-150.	2.2	38
61	The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. <i>Thrombosis Journal</i> , 2017, 15, 17.	2.1	38
62	Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 229-233.	1.7	37
63	Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 1994, 71, 192-4.	3.4	37
64	Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). <i>American Journal of Hematology</i> , 1991, 38, 86-89.	4.1	36
65	The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. <i>International Journal of Hematology</i> , 2010, 92, 302-305.	1.6	35
66	Modified nonovert DIC diagnostic criteria predict the early phase of overtDIC. <i>American Journal of Hematology</i> , 2010, 85, 691-694.	4.1	35
67	Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1088-1099.	1.6	35
68	Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. <i>Expert Review of Hematology</i> , 2012, 5, 643-652.	2.2	33
69	Natural History of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 866-873.	2.7	33
70	High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. <i>American Journal of Hematology</i> , 2004, 76, 338-342.	4.1	32
71	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. <i>Archives of Medical Research</i> , 2021, 52, 788-797.	3.3	32
72	Hemostatic Molecular Markers Before Onset of Disseminated Intravascular Coagulation in Leukemic Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 293-297.	2.7	31

#	ARTICLE	IF	CITATIONS
73	Increased Soluble Fibrin in Plasma of Patients with Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 233-240.	1.7	31
74	Decreased ADAMTS13 Levels in Patients after Living Donor Liver Transplantation. <i>Thrombosis Research</i> , 2009, 124, 541-545.	1.7	31
75	Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. <i>American Journal of Hematology</i> , 1995, 50, 237-243.	4.1	30
76	Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. <i>American Journal of Hematology</i> , 1995, 49, 1-5.	4.1	29
77	Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan", <i>Thrombosis Research</i> , 2014, 134, 924-925.	1.7	29
78	Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. <i>Thrombosis Research</i> , 2014, 133, 440-444.	1.7	29
79	Plasminogen activators and their inhibitors in leukemic cell homogenates. <i>American Journal of Hematology</i> , 1993, 42, 166-170.	4.1	28
80	Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. <i>American Journal of Hematology</i> , 2000, 65, 35-40.	4.1	28
81	Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. <i>Thrombosis Research</i> , 2010, 126, 18-23.	1.7	27
82	Update on the Clot Waveform Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962091202.	1.7	27
83	Hypercoagulable State in the Watanabe Heritable Hyperlipidemic Rabbit, an Animal Model for the Progression of Atherosclerosis. <i>Thrombosis and Haemostasis</i> , 1989, 61, 140-143.	3.4	27
84	Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, 627-633.	1.0	26
85	Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. , 1999, 61, 238-242.		26
86	Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 5-9.	1.7	26
87	Frequency and hemostatic abnormalities in pre-DIC patients. <i>Thrombosis Research</i> , 2010, 126, 74-78.	1.7	26
88	Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1665-1666.	3.8	26
89	Increased activated protein C-protein C inhibitor complex level in patients positive for lupus anticoagulant. <i>Blood Coagulation and Fibrinolysis</i> , 1994, 5, 173-178.	1.0	25
90	Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. <i>Thrombosis Journal</i> , 2019, 17, 12.	2.1	25

#	ARTICLE	IF	CITATIONS
91	Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. <i>Blood Coagulation and Fibrinolysis</i> , 1998, 9, 491-498.	1.0	24
92	Comparison of the Responses of Global Tests of Coagulation with Molecular Markers of Neutrophil, Endothelial, and Hemostatic System Perturbation in the Baboon Model of E. coli Sepsis. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1489-1494.	3.4	24
93	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882404.	1.7	24
94	Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 017-022.	2.7	24
95	An Evaluation of the Activated Partial Thromboplastin Time Waveform. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 764-770.	1.7	23
96	Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. <i>Thrombosis and Haemostasis</i> , 2003, 89, 660-665.	3.4	22
97	Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. <i>Thrombosis and Haemostasis</i> , 2004, 92, 132-139.	3.4	22
98	Elevated Plasma Levels of Fibrin Degradation Products by Granulocyte-Derived Elastase in Patients with Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 391-400.	1.7	22
99	Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux. <i>International Journal of Hematology</i> , 2012, 95, 160-166.	1.6	22
100	Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2078-2079.	3.8	22
101	Hypercoagulant states in malignant lymphoma. <i>Experimental Oncology</i> , 2005, 27, 179-85.	0.1	22
102	The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. <i>Clinica Chimica Acta</i> , 2013, 425, 109-113.	1.1	20
103	Elevated Fibrin-related Markers in Patients with Malignant Diseases Frequently Associated with Disseminated Intravascular Coagulation and Venous Thromboembolism. <i>Internal Medicine</i> , 2014, 53, 413-419.	0.7	20
104	Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura. <i>Internal Medicine</i> , 2016, 55, 589-595.	0.7	20
105	Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. <i>Thrombosis Research</i> , 2007, 119, 447-452.	1.7	19
106	Elevated levels of soluble fibrin in patients with venous thromboembolism. <i>International Journal of Hematology</i> , 2008, 88, 448-453.	1.6	19
107	Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation. <i>Thrombosis Research</i> , 2013, 131, 225-229.	1.7	19
108	Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy. <i>Thrombosis Research</i> , 2019, 178, 54-58.	1.7	19



#	ARTICLE	IF	CITATIONS
109	PROTEINASE 3 EXPRESSION ON NEUTROPHIL MEMBRANES FROM PATIENTS WITH INFECTIOUS DISEASE. Shock, 2006, 26, 128-133.	2.1	18
110	Soluble C-Type Lectin-Like Receptor 2 Elevation in Patients with Acute Cerebral Infarction. Journal of Clinical Medicine, 2021, 10, 3408.	2.4	18
111	Hemodynamic and Morphological Changes in the Dog Kidney after Injection of 5% Ethanolamine Oleate into the Superior Vena cava. European Surgical Research, 1990, 22, 63-70.	1.3	17
112	A Prospective Analysis of Disseminated Intravascular Coagulation in Patients with Infections. Internal Medicine, 2013, 52, 1893-1898.	0.7	17
113	Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection. Journal of Clinical Medicine, 2021, 10, 3775.	2.4	17
114	Platelet Activation and Thrombosis in COVID-19. Seminars in Thrombosis and Hemostasis, 2023, 49, 055-061.	2.7	17
115	ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA). Thrombosis Research, 2008, 121, 849-854.	1.7	16
116	Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement. International Journal of Hematology, 2011, 94, 355-360.	1.6	16
117	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thrombosis Research, 2016, 145, 46-50.	1.7	16
118	Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform. International Journal of Laboratory Hematology, 2018, 40, 49-55.	1.3	16
119	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. International Journal of Hematology, 2021, 113, 330-336.	1.6	16
120	Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2021, 10, 2860.	2.4	16
121	Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. International Journal of Hematology, 2011, 93, 47-52.	1.6	15
122	Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. International Journal of Hematology, 2014, 100, 450-456.	1.6	15
123	Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients. International Journal of Hematology, 2014, 99, 437-440.	1.6	15
124	Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery. International Journal of Hematology, 2016, 103, 560-566.	1.6	15
125	The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC. International Journal of Hematology, 2016, 103, 173-179.	1.6	14
126	An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1170-1176.	1.7	14



#	ARTICLE	IF	CITATIONS
127	Plasma level of IL-1 beta in disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 1991, 65, 364-8.	3.4	14
128	Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. <i>Journal of Clinical Medicine</i> , 2022, 11, 985.	2.4	14
129	More on: racial differences in venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 319-320.	3.8	13
130	Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, e137-e139.	0.6	13
131	Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor. <i>Thrombosis Research</i> , 2020, 193, 146-153.	1.7	13
132	Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure. <i>Thrombosis Journal</i> , 2020, 18, 2.	2.1	13
133	Analysis of the Cutoff Values in Fibrin-Related Markers for the Diagnosis of Overt DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 495-500.	1.7	12
134	Frequent association of thrombophilia in cerebral venous sinus thrombosis. <i>International Journal of Hematology</i> , 2012, 95, 257-262.	1.6	12
135	An Evaluation of the Modified Diagnostic Criteria for DIC Established by the Japanese Society of Thrombosis and Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 579-584.	1.7	12
136	Evaluation of the Diagnostic Criteria for the Basic Type of DIC Established by the Japanese Society of Thrombosis and Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 838-843.	1.7	12
137	Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the <i>C3</i> p.I1157T Variation in the Kinki Region of Japan. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1301-1307.	1.7	12
138	Elevated D-Dimer Levels Predict a Poor Outcome in Critically Ill Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962097308.	1.7	12
139	Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. <i>Translational Research</i> , 1992, 119, 682-9.	2.3	12
140	Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases. <i>International Journal of Hematology</i> , 2013, 97, 345-350.	1.6	11
141	Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function. <i>International Journal of Hematology</i> , 2014, 99, 418-428.	1.6	11
142	The Evaluation of Fibrin-Related Markers for Diagnosing or Predicting Acute or Subclinical Venous Thromboembolism in Patients Undergoing Major Orthopedic Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 107-114.	1.7	11
143	The Evaluation of D-Dimer Levels for the Comparison of Fibrinogen and Fibrin Units Using Different D-Dimer Kits to Diagnose VTE. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 655-662.	1.7	11
144	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 145S-149S.	1.7	11

#	ARTICLE	IF	CITATIONS
145	Nerve Endings in Palm Skin Grafts. <i>Annals of Plastic Surgery</i> , 1989, 22, 461-466.	0.9	10
146	Plasma levels of activated FVII in various diseases. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 794-798.	1.0	10
147	Hypofibrinogenemia and the $\hat{\pm}$ -Fibrinogen Thr312Ala Polymorphism may be Risk Factors for Early Pregnancy Loss. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 52-57.	1.7	10
148	Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 622-630.	1.7	10
149	Anticoagulant Activity in Cell Homogenate of Adult T Cell Leukemia. <i>Thrombosis and Haemostasis</i> , 1988, 59, 197-201.	3.4	10
150	Diffuse brain damage caused by acute twin-twin transfusion during late pregnancy. <i>Pediatrics International</i> , 1998, 40, 370-373.	0.5	9
151	Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. <i>American Journal of Hematology</i> , 2005, 78, 1-6.	4.1	9
152	Analysis three abnormal Protein S genes in a patient with pulmonary embolism. <i>Thrombosis Research</i> , 2010, 125, 529-532.	1.7	9
153	Increased Ratio of Soluble Fibrin Formation/Thrombin Generation in Patients With DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 628-632.	1.7	9
154	Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097548.	1.7	9
155	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4840.	2.4	9
156	Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation. <i>Thrombosis and Haemostasis</i> , 1989, 61, 140-3.	3.4	9
157	Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. <i>Thrombosis and Haemostasis</i> , 2003, 89, 660-5.	3.4	9
158	Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. <i>American Journal of Hematology</i> , 2000, 65, 210-214.	4.1	8
159	Effects of Lipid Abnormalities on Arteriosclerosis and Hemostatic Markers in Patients under Hemodialysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 203-210.	1.7	8
160	A second national questionnaire survey of TMA. <i>International Journal of Hematology</i> , 2010, 92, 68-75.	1.6	8
161	High frequency of decreased antithrombin level in pregnant women with thrombosis. <i>International Journal of Hematology</i> , 2015, 102, 253-258.	1.6	8
162	Platelet Activation Assessed by Glycoprotein VI/Platelet Ratio Is Associated With Portal Vein Thrombosis After Hepatectomy and Splenectomy in Patients With Liver Cirrhosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 254-262.	1.7	8

#	ARTICLE	IF	CITATIONS
163	Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. <i>Thrombosis Journal</i> , 2021, 19, 12.	2.1	8
164	Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C. <i>American Journal of Hematology</i> , 1993, 44, 218-219.	4.1	7
165	State-of-the-Art Review : Outcome of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Japan. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 110-112.	1.7	7
166	State-of-the-Art Review : Coagulation Tests and Anti-Phospholipid Antibodies in Patients Positive for Lupus Anticoagulant. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2000, 6, 144-150.	1.7	7
167	Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 17-24.	1.0	7
168	Is early treatment of disseminated intravascular coagulation beneficial in septic patients?. <i>Critical Care</i> , 2014, 18, 447.	5.8	7
169	The valuable diagnosis of DIC and pre-DIC and prediction of a poor outcome by the evaluation of diagnostic criteria for DIC in patients with hematopoietic injury established by the Japanese Society of Thrombosis and Hemostasis. <i>Thrombosis Research</i> , 2016, 147, 80-84.	1.7	7
170	Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis. <i>Thrombosis Research</i> , 2021, 201, 154-160.	1.7	7
171	The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097691.	1.7	7
172	The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110120.	1.7	7
173	A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 5352.	2.4	7
174	D-dimer kit with a High FDP/D-Dimer Ratio is Useful for Diagnosing Thrombotic Diseases. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110705.	1.7	7
175	Elevated Fibrin-Related Markers in Patients with Malignant Diseases Suspected of Having Thrombotic Disorders. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 266-272.	1.7	6
176	Anti-Xa activity in VTE patients treated with fondaparinux. <i>Clinica Chimica Acta</i> , 2015, 442, 22-23.	1.1	6
177	Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux. <i>International Journal of Hematology</i> , 2016, 103, 554-559.	1.6	6
178	High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism. <i>International Journal of Hematology</i> , 2017, 105, 272-279.	1.6	6
179	The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 920-927.	1.7	6
180	National questionnaire survey of TMA. <i>International Journal of Hematology</i> , 2009, 90, 328-335.	1.6	5

#	ARTICLE	IF	CITATIONS
181	A novel protein S gene mutation combined with protein S Tokushima mutation in a patient with superior sagittal sinus thrombosis. <i>Journal of Neurology</i> , 2012, 259, 178-179.	3.6	5
182	The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1506-1507.	3.8	5
183	Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 436-442.	2.8	5
184	Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment—A Cohort Study Using a Postmarketing Surveillance Database. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110540.	1.7	5
185	Spa Bathing Activates Fibrinolysis in Patients with Cerebral Infarction.. <i>Internal Medicine</i> , 1993, 32, 619-622.	0.7	4
186	Stimulation of tissue type plasminogen activator by leukaemic cell homogenates. <i>Blood Coagulation and Fibrinolysis</i> , 1993, 4, 591-598.	1.0	4
187	Increased Plasma Soluble-adhesion Molecules in Thrombotic Thrombocytopenic Purpura and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1998, 4, 196-200.	1.7	4
188	Analyses of Serum Concentrations of Apolipoproteins in the Demented Elderly.. <i>Internal Medicine</i> , 2000, 39, 220-222.	0.7	4
189	Lethal hepatic infarction following plasma exchange in living donor liver transplant patients. <i>Transplant International</i> , 2011, 24, e57-e58.	1.6	4
190	Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 555-556.	3.8	4
191	Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094111.	1.7	4
192	An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1566-1574.	1.3	4
193	Proposal of Quick Diagnostic Criteria for Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1028.	2.4	4
194	Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura. <i>Journal of Clinical Medicine</i> , 2021, 10, 5987.	2.4	4
195	Mammalian Histidine Decarboxylase and DOPA Decarboxylase. <i>Annals of the New York Academy of Sciences</i> , 1990, 585, 145-161.	3.8	3
196	Pathophysiology and diagnostic criteria for disseminated intravascular coagulation associated with sepsis*. <i>Critical Care Medicine</i> , 2008, 36, 348-349.	0.9	3
197	Two Patients with Antiphospholipid Antibody Developed Disseminated Intravascular Coagulation. <i>Internal Medicine</i> , 2013, 52, 269-272.	0.7	3
198	Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 684-685.	3.8	3

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2308-2309.	3.8	3
200	Elevated Soluble Platelet Glycoprotein VI Levels in Patients After Living Donor Liver Transplantation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 274-281.	1.7	3
201	Protection From Pregnancy Loss in Women With Hereditary Thrombophilia When Associated With Fibrinogen Polymorphism Thr331Ala. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 494-495.	1.7	3
202	Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant. <i>Thrombosis Journal</i> , 2017, 15, 27.	2.1	3
203	Anticoagulant activity in cell homogenate of adult T cell leukemia. <i>Thrombosis and Haemostasis</i> , 1988, 59, 197-201.	3.4	3
204	Effect of inorganic phosphate and ADP on the myofilament sliding induced by laser flash photolysis of caged ATP. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1996, 1274, 89-93.	1.0	2
205	Prevention of venous thromboembolism according to the guidelines of a domestic manual. <i>International Journal of Hematology</i> , 2010, 91, 909-911.	1.6	2
206	Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 679-680.	3.8	2
207	Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1314-1315.	3.8	2
208	APTT waveform. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2018, 29, 413-420.	0.1	2
209	Comments to: An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia by APTT Waveform, Peak Heights of APTT Waveform Are Useful for Diagnosing Hemophilia or Inhibitor. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882441.	1.7	2
210	The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome. <i>Thrombosis Update</i> , 2020, 1, 100012.	0.9	2
211	Coagulation factor V inhibitors, a review of the case report literature. <i>Thrombosis Update</i> , 2021, 4, 100058.	0.9	2
212	Molecular characterization of coagulation factor XII deficiency in a Japanese family. <i>Thrombosis and Haemostasis</i> , 2003, 90, 59-63.	3.4	2
213	Scores biologiques deÂCIVD. <i>Sang Thrombose Vaisseaux</i> , 2010, 22, 003-005.	0.1	1
214	Platelets Activation and Liver Transplantation. <i>Journal of Liver</i> , 2017, 06, .	0.3	1
215	Congenital Thrombophilia in Patients With Superior Mesenteric Venous Thrombosis or Portal Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1117-1121.	1.7	1
216	Major bleeding in a patient with warfarin-hypersensitive and factor IX propeptide variant, p.Ala37Thr, who was treated with a direct oral anti-Xa inhibitor. <i>Annals of Hematology</i> , 2019, 98, 209-210.	1.8	1

#	ARTICLE	IF	CITATIONS
217	Errors in the diagnosis for DIC due to a statistical misunderstanding. Journal of Thrombosis and Haemostasis, 2020, 18, 1791-1792.	3.8	1
218	Effect of Pravastatin® on Coagulation and Fibrinolytic Systems in Patients with Hypercholesterolemia. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 501-504.	0.1	1
219	EFFECT OF THE LIPOPROTEIN FRACTION FROM PLASMA-EUGLOBULIN ON THE PLASMINOGEN ACTIVATION. Thrombosis and Haemostasis, 1987, 58, 1578.	3.4	0
220	Disseminated mycobacterial infection in a hemophilia B patient with acquired immunodeficiency syndrome.. Japanese Journal of Medicine, 1990, 29, 442-447.	0.1	0
221	Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis. Vascular Disease Prevention, 2008, 5, 81-88.	0.2	0
222	Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State. Vascular Disease Prevention, 2008, 5, 227-233.	0.2	0
223	Difference between sepsis and trauma diagnosed as sensitive diagnostic criteria for disseminated intravascular coagulation. Thrombosis and Haemostasis, 2008, 100, 958-959.	3.4	0
224	Neutrophil elastase affects not only tissue damage, but it also regulates hematopoiesis. Thrombosis Research, 2011, 128, 205-206.	1.7	0
225	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is "shock liver"™ the unrecognized provocateur of ischemic limb necrosis: comment. Journal of Thrombosis and Haemostasis, 2016, 14, 2315-2316.	3.8	0
226	Increased Membrane Proteinase 3 Expression on Neutrophils in Patients with Infectious Disease.. Blood, 2004, 104, 3806-3806.	1.4	0
227	Initial Laboratory Findings Useful for Predicting the Diagnosis of Chronic ITP: Results of a Multicenter Prospective Study.. Blood, 2004, 104, 2061-2061.	1.4	0
228	Annexin II overexpression correlates with a poor prognosis in surgically resected non-small-cell lung cancer. Journal of Clinical Oncology, 2005, 23, 7249-7249.	1.6	0
229	Physiological Protease Inhibitor α <sub>2</sub> AT, APC. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 6-8.	0.1	0
230	Diagnostic criteria for DIC based on the prospective study. Japanese Journal of Thrombosis and Hemostasis, 2010, 21, 600-605.	0.1	0
231	Clinical Practice in Hemophilia and Thrombophilia Center in Mie University. Japanese Journal of Thrombosis and Hemostasis, 2010, 21, 640-641.	0.1	0
232	PCR Analysis of Bacteria and Fungi in Early Phase of Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1963-1963.	1.4	0
233	Modification of factor VIII by thrombin and factor Xa. Blood & Vessel, 1984, 15, 178-182.	0.0	0
234	Studies on platelet-activating factor (PAF) Effect of antiplatelet agents on the release of PAF from human platelets.. Blood & Vessel, 1984, 15, 507-509.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Coagulability in Watanabe heritable hyperlipidemic(WHHL) rabbit.. Blood & Vessel, 1987, 18, 482-485.	0.0	0
236	Effect of tissue-type plasminogen activator on platelet aggregation.. Blood & Vessel, 1988, 19, 636-639.	0.0	0
237	Platelet Function in Watanabe Heritable Hyperlipidemic Rabbits, a Model for the Progression of Atherosclerosis. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 29-33.	0.1	0
238	The Hypercoagulable State in Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1991, 19, 829-832.	0.0	0
239	The Clinical Significance of Automatically Measured D-Dimer and its Relationship to Fibrin Degradation Products. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 511-517.	0.1	0
240	Effect of Niceritrol on Coagulation and Fibrinolytic Systems in Patients with Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1992, 20, 1005-1008.	0.0	0